phytomenadione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2843 84-80-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vitamin K1
  • phytomenadione
  • vitamin K
  • phytonadione
  • phytylmenadione
  • phytylmenaquinone
  • phylloquinone
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
  • Molecular weight: 450.71
  • Formula: C31H46O2
  • CLOGP: 11.69
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS: -6.88
  • ROTB: 14
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O
20 mg P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.32 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.60 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.30 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 60
kinase-selectivity-class AXL,BRAF,CAMK2D,CDK4,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK12,MAPK7,STK33,TEK,TTK 14
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
May 18, 2000 FDA SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 208.09 13.61 71 12499 10208 90605669
International normalised ratio increased 97.71 13.61 68 12502 47248 90568629
Coagulopathy 87.56 13.61 49 12521 23240 90592637
Sepsis 84.51 13.61 114 12456 179700 90436177
Ascites 72.43 13.61 57 12513 47683 90568194
Multiple organ dysfunction syndrome 67.83 13.61 64 12506 68272 90547605
Toxic epidermal necrolysis 58.52 13.61 43 12527 32485 90583392
Hepatic failure 52.98 13.61 44 12526 39684 90576193
Cystic fibrosis 48.98 13.61 19 12551 3922 90611955
Injury associated with device 46.69 13.61 19 12551 4445 90611432
Stevens-Johnson syndrome 46.55 13.61 36 12534 29340 90586537
Renal vascular thrombosis 44.17 13.61 8 12562 77 90615800
Cholestasis 43.89 13.61 38 12532 36261 90579616
Symmetrical drug-related intertriginous and flexural exanthema 41.92 13.61 12 12558 967 90614910
Thrombocytopenia 40.05 13.61 89 12481 208636 90407241
Pancreatitis acute 39.59 13.61 34 12536 32081 90583796
Arthropathy 39.40 13.61 3 12567 366239 90249638
Activated partial thromboplastin time prolonged 39.38 13.61 20 12550 7805 90608072
Acute hepatic failure 38.73 13.61 29 12541 22532 90593345
Factor V inhibition 38.59 13.61 8 12562 163 90615714
Premature baby 31.83 13.61 27 12543 25050 90590827
Hepatic encephalopathy 31.27 13.61 21 12549 13751 90602126
Hypokalaemia 31.08 13.61 61 12509 131055 90484822
Osteochondritis 30.81 13.61 5 12565 23 90615854
Anaemia 29.83 13.61 112 12458 352690 90263187
Neonatal disorder 28.72 13.61 8 12562 584 90615293
Acute respiratory distress syndrome 28.70 13.61 27 12543 28659 90587218
Therapeutic product effect decreased 27.89 13.61 3 12567 277568 90338309
Rheumatoid arthritis 27.66 13.61 8 12562 362606 90253271
Pleural effusion 27.64 13.61 53 12517 111938 90503939
Systemic lupus erythematosus 27.57 13.61 8 12562 361888 90253989
Retroperitoneal haematoma 27.43 13.61 12 12558 3356 90612521
Hypersensitivity 26.61 13.61 15 12555 454662 90161215
Haemorrhage neonatal 26.60 13.61 5 12565 60 90615817
Wound 26.43 13.61 5 12565 302975 90312902
Superior sagittal sinus thrombosis 26.28 13.61 8 12562 798 90615079
Pancreatitis chronic 26.01 13.61 11 12559 2832 90613045
Acute kidney injury 25.67 13.61 100 12470 320287 90295590
Vitamin K deficiency 25.30 13.61 7 12563 498 90615379
Prothrombin time prolonged 24.86 13.61 16 12554 9756 90606121
Drug reaction with eosinophilia and systemic symptoms 24.59 13.61 30 12540 42728 90573149
Contraindicated product administered 24.53 13.61 7 12563 320132 90295745
Aspartate aminotransferase increased 24.52 13.61 48 12522 102889 90512988
Treatment failure 24.51 13.61 6 12564 303922 90311955
Drug intolerance 24.47 13.61 16 12554 447575 90168302
Transverse sinus thrombosis 23.92 13.61 7 12563 610 90615267
Haemoptysis 23.55 13.61 26 12544 33294 90582583
Blood alkaline phosphatase increased 23.33 13.61 31 12539 48048 90567829
Hyperphosphataemia 23.20 13.61 11 12559 3700 90612177
Epidermolysis 22.96 13.61 7 12563 702 90615175
Blood bilirubin increased 22.60 13.61 29 12541 43441 90572436
Haemorrhage 22.49 13.61 37 12533 69332 90546545
Gamma-glutamyltransferase increased 22.43 13.61 27 12543 37925 90577952
Suspected transmission of an infectious agent via product 22.08 13.61 6 12564 399 90615478
Epistaxis 21.88 13.61 41 12529 85084 90530793
Haematoma 21.81 13.61 27 12543 39021 90576856
Haematemesis 21.60 13.61 25 12545 33701 90582176
Helicobacter infection 21.45 13.61 3 12567 226847 90389030
Disseminated intravascular coagulation 21.03 13.61 20 12550 21518 90594359
Respiratory failure 21.03 13.61 49 12521 118369 90497508
Sleep disorder therapy 21.00 13.61 6 12564 480 90615397
Neonatal anuria 20.91 13.61 4 12566 53 90615824
Low birth weight baby 20.45 13.61 14 12556 9453 90606424
Factor VII deficiency 20.15 13.61 4 12566 65 90615812
Necrotising enterocolitis neonatal 19.97 13.61 5 12565 241 90615636
Hyperbilirubinaemia 19.76 13.61 16 12554 13920 90601957
Nipple disorder 19.64 13.61 5 12565 258 90615619
Transaminases increased 19.63 13.61 25 12545 37167 90578710
Febrile neutropenia 19.37 13.61 57 12513 158292 90457585
Analgesic therapy 19.08 13.61 6 12564 666 90615211
Renal failure 18.82 13.61 50 12520 130957 90484920
Bilirubin conjugated increased 18.72 13.61 9 12561 3121 90612756
Antacid therapy 18.40 13.61 6 12564 748 90615129
Appendicolith 18.35 13.61 6 12564 755 90615122
Foetal exposure during pregnancy 18.27 13.61 26 12544 42949 90572928
Mobility decreased 18.27 13.61 6 12564 250728 90365149
Joint swelling 18.21 13.61 26 12544 503274 90112603
Pain 18.14 13.61 74 12496 996267 89619610
Intestinal dilatation 18.06 13.61 8 12562 2302 90613575
Drug therapy 17.99 13.61 6 12564 803 90615074
Anticoagulant therapy 17.93 13.61 6 12564 811 90615066
Injury 17.76 13.61 3 12567 197346 90418531
Septic shock 17.38 13.61 37 12533 84123 90531754
Subdural haematoma 17.29 13.61 16 12554 16629 90599248
Epicondylitis 17.18 13.61 8 12562 2586 90613291
Mouth haemorrhage 17.03 13.61 12 12558 8489 90607388
Hepatic enzyme increased 17.01 13.61 15 12555 360721 90255156
Abdominal distension 16.93 13.61 48 12522 130553 90485324
Hypophosphataemia 16.85 13.61 15 12555 14839 90601038
HER2 positive breast cancer 16.77 13.61 5 12565 465 90615412
Fibromyalgia 16.76 13.61 4 12566 206265 90409612
Pelvic fluid collection 16.41 13.61 6 12564 1053 90614824
Oligohydramnios 16.39 13.61 11 12559 7190 90608687
Thrombocytopenic purpura 16.36 13.61 7 12563 1854 90614023
Hepatocellular injury 16.13 13.61 20 12550 28938 90586939
Blood creatinine increased 15.91 13.61 40 12530 101346 90514531
Anticoagulation drug level above therapeutic 15.80 13.61 7 12563 2015 90613862
Pulmonary function test decreased 15.66 13.61 9 12561 4485 90611392
Terminal ileitis 15.44 13.61 6 12564 1244 90614633
Blood urea increased 15.35 13.61 20 12550 30393 90585484
Product use issue 15.22 13.61 14 12556 329905 90285972
Vitamin A deficiency 15.10 13.61 3 12567 49 90615828
Exposure via breast milk 14.90 13.61 7 12563 2308 90613569
Jugular vein thrombosis 14.73 13.61 8 12562 3573 90612304
Discomfort 14.72 13.61 10 12560 274325 90341552
Pulmonary pain 14.58 13.61 9 12561 5105 90610772
Maternal drugs affecting foetus 14.51 13.61 9 12561 5146 90610731
Jaundice 14.31 13.61 20 12550 32497 90583380
Skin abrasion 14.06 13.61 12 12558 11223 90604654
Hepatosplenic candidiasis 13.90 13.61 4 12566 328 90615549
Alanine aminotransferase increased 13.90 13.61 42 12528 118296 90497581
Cardiogenic shock 13.79 13.61 17 12553 24451 90591426
Foetal growth restriction 13.79 13.61 11 12559 9369 90606508
Infusion related reaction 13.66 13.61 23 12547 416757 90199120
Neutropenic colitis 13.65 13.61 8 12562 4135 90611742
Serratia sepsis 13.63 13.61 3 12567 82 90615795

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 517.16 17.01 207 20354 13249 42587525
Appendicitis 462.99 17.01 217 20344 20396 42580378
Ascites 358.79 17.01 262 20299 56416 42544358
Cardiogenic shock 331.14 17.01 209 20352 35431 42565343
Ventricular fibrillation 308.57 17.01 188 20373 29935 42570839
Stress 304.02 17.01 215 20346 43997 42556777
Abdominal distension 298.15 17.01 259 20302 71476 42529298
Multiple organ dysfunction syndrome 283.49 17.01 288 20273 96747 42504027
Blood phosphorus increased 266.17 17.01 127 20434 12398 42588376
Myasthenia gravis 246.97 17.01 131 20430 16006 42584768
Hyperphosphataemia 240.73 17.01 120 20441 12884 42587890
Sleep disorder therapy 216.97 17.01 92 20469 6802 42593972
Hypophosphataemia 197.33 17.01 124 20437 20821 42579953
Hyponatraemia 196.24 17.01 243 20318 101219 42499555
Incorrect route of product administration 190.01 17.01 128 20433 24177 42576597
Analgesic therapy 188.63 17.01 82 20479 6442 42594332
Activated partial thromboplastin time prolonged 185.53 17.01 108 20453 15795 42584979
Drug therapy 177.35 17.01 78 20483 6302 42594472
Blood uric acid increased 171.94 17.01 102 20459 15445 42585329
Infective pulmonary exacerbation of cystic fibrosis 162.19 17.01 78 20483 7740 42593034
Neuralgia 160.76 17.01 118 20443 25529 42575245
Bacterial infection 158.55 17.01 121 20440 27758 42573016
Blood cholesterol increased 149.74 17.01 115 20446 26626 42574148
Antacid therapy 148.58 17.01 63 20498 4654 42596120
Sepsis 147.80 17.01 308 20253 199026 42401748
Iron deficiency 144.79 17.01 81 20480 10980 42589794
Dry mouth 141.77 17.01 132 20429 39747 42561027
Anticoagulant therapy 140.96 17.01 60 20501 4475 42596299
General physical health deterioration 129.14 17.01 248 20313 150998 42449776
Abdominal pain 123.62 17.01 279 20282 190192 42410582
Blood calcium increased 116.37 17.01 64 20497 8390 42592384
End stage renal disease 114.76 17.01 81 20480 16477 42584297
Ulcer 110.65 17.01 79 20482 16362 42584412
Sleep disorder 100.62 17.01 120 20441 47975 42552799
Total lung capacity decreased 100.35 17.01 44 20517 3526 42597248
Constipation 98.89 17.01 232 20329 162059 42438715
Diabetes mellitus 95.84 17.01 131 20430 59956 42540818
Swelling 94.17 17.01 124 20437 54761 42546013
Aortic stenosis 93.09 17.01 56 20505 8689 42592085
Bronchopulmonary aspergillosis allergic 92.71 17.01 45 20516 4553 42596221
Blood test abnormal 91.44 17.01 64 20497 12842 42587932
Chronic obstructive pulmonary disease 89.39 17.01 130 20431 62984 42537790
Gout 88.55 17.01 87 20474 27968 42572806
Hyperlipidaemia 83.81 17.01 75 20486 21441 42579333
Troponin increased 81.37 17.01 70 20491 18992 42581782
Thrombosis 79.94 17.01 129 20432 68382 42532392
Intentional product misuse 78.37 17.01 121 20440 61779 42538995
Congenital hiatus hernia 77.50 17.01 44 20517 6130 42594644
Vomiting 68.77 17.01 299 20262 289424 42311350
Toxic epidermal necrolysis 64.76 17.01 72 20489 26678 42574096
Drug hypersensitivity 64.76 17.01 146 20415 99243 42501531
Lung opacity 63.73 17.01 38 20523 5799 42594975
Bacteroides infection 63.49 17.01 29 20532 2558 42598216
Hyper IgE syndrome 62.54 17.01 15 20546 163 42600611
Toxicity to various agents 58.29 17.01 19 20542 229117 42371657
Somnolence 57.65 17.01 174 20387 140931 42459843
Lower respiratory tract infection 57.04 17.01 84 20477 41122 42559652
Pleuritic pain 54.61 17.01 37 20524 7040 42593734
Pulmonary embolism 53.14 17.01 152 20409 119460 42481314
Drug intolerance 47.81 17.01 114 20447 80310 42520464
Aspiration 46.52 17.01 50 20511 17836 42582938
Dizziness 44.76 17.01 33 20528 249221 42351553
Micturition urgency 41.50 17.01 39 20522 11859 42588915
Transaminases increased 41.19 17.01 64 20497 32821 42567953
International normalised ratio increased 39.77 17.01 78 20483 48090 42552684
Liver function test increased 38.70 17.01 48 20513 19950 42580824
Cystic fibrosis 38.11 17.01 19 20542 2036 42598738
Breath sounds abnormal 37.21 17.01 37 20524 12056 42588718
Benign prostatic hyperplasia 35.20 17.01 47 20514 21005 42579769
Myocardial infarction 33.84 17.01 9 20552 124000 42476774
Sputum discoloured 33.03 17.01 32 20529 10100 42590674
Joint injury 32.96 17.01 38 20523 14638 42586136
Fall 32.73 17.01 39 20522 234481 42366293
Cardiovascular disorder 30.68 17.01 35 20526 13330 42587444
Arthralgia 29.86 17.01 33 20528 205205 42395569
Respiratory symptom 28.79 17.01 31 20530 11075 42589699
Hypercholesterolaemia 28.40 17.01 33 20528 12816 42587958
Fatigue 27.28 17.01 113 20448 435528 42165246
Liver disorder 26.63 17.01 59 20502 39585 42561189
Pruritus 25.68 17.01 32 20529 188739 42412035
Drug ineffective 25.50 17.01 189 20372 630008 41970766
Gait disturbance 25.10 17.01 8 20553 97992 42502782
Cutaneous mucormycosis 25.01 17.01 10 20551 635 42600139
Anaemia 24.99 17.01 225 20336 280053 42320721
Malaise 24.86 17.01 40 20521 212116 42388658
Condition aggravated 24.63 17.01 212 20349 260542 42340232
Peripheral swelling 23.78 17.01 7 20554 90263 42510511
Discoloured vomit 23.28 17.01 10 20551 762 42600012
Hepatic failure 22.61 17.01 54 20507 38046 42562728
Diarrhoea 22.24 17.01 131 20430 460718 42140056
Intentional product use issue 22.04 17.01 4 20557 71829 42528945
Rash 21.89 17.01 65 20496 276889 42323885
Back pain 21.49 17.01 22 20539 141754 42459020
Depression 20.93 17.01 14 20547 111349 42489425
Musculoskeletal stiffness 19.68 17.01 67 20494 57698 42543076
Pneumonia staphylococcal 19.55 17.01 15 20546 3461 42597313
Nausea 19.27 17.01 283 20278 396516 42204258
Cystic fibrosis related diabetes 18.94 17.01 6 20555 192 42600582
Disease progression 18.86 17.01 25 20536 143631 42457143
Joint swelling 18.43 17.01 5 20556 68017 42532757
Rubber sensitivity 18.20 17.01 7 20554 401 42600373
Death 17.74 17.01 144 20417 471041 42129733
Asthma 17.60 17.01 68 20493 62246 42538528
Cortical visual impairment 17.56 17.01 4 20557 34 42600740
Hyphaema 17.44 17.01 8 20553 712 42600062

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 642.42 14.31 213 30227 14042 110544817
Appendicitis 532.33 14.31 223 30217 28241 110530618
Ascites 483.17 14.31 307 30133 92501 110466358
Multiple organ dysfunction syndrome 412.01 14.31 338 30102 151372 110407487
Cardiogenic shock 386.71 14.31 224 30216 57114 110501745
Ventricular fibrillation 373.95 14.31 196 30244 41117 110517742
Blood phosphorus increased 325.61 14.31 134 30306 16206 110542653
Infective pulmonary exacerbation of cystic fibrosis 321.30 14.31 129 30311 14642 110544217
Hyperphosphataemia 318.51 14.31 132 30308 16249 110542610
Myasthenia gravis 302.74 14.31 138 30302 21373 110537486
Sleep disorder therapy 286.75 14.31 99 30341 7372 110551487
Abdominal distension 285.01 14.31 293 30147 174810 110384049
Sepsis 278.94 14.31 394 30046 326952 110231907
Stress 269.75 14.31 227 30213 105121 110453738
Activated partial thromboplastin time prolonged 254.72 14.31 124 30316 22244 110536615
Analgesic therapy 250.71 14.31 89 30351 7195 110551664
Hypophosphataemia 248.84 14.31 139 30301 33043 110525816
Drug therapy 235.54 14.31 85 30355 7206 110551653
Blood uric acid increased 214.51 14.31 109 30331 21420 110537439
Antacid therapy 196.33 14.31 69 30371 5415 110553444
Hyponatraemia 194.13 14.31 268 30172 217385 110341474
Bacterial infection 190.24 14.31 132 30308 45904 110512955
Anticoagulant therapy 186.38 14.31 66 30374 5295 110553564
Neuralgia 170.45 14.31 126 30314 48352 110510507
Iron deficiency 168.08 14.31 88 30352 18388 110540471
Incorrect route of product administration 157.65 14.31 135 30305 63926 110494933
End stage renal disease 155.68 14.31 88 30352 21385 110537474
Gout 135.23 14.31 98 30342 36468 110522391
Blood calcium increased 125.58 14.31 72 30368 17968 110540891
Toxic epidermal necrolysis 124.44 14.31 112 30328 56615 110502244
Aortic stenosis 123.94 14.31 64 30376 12995 110545864
International normalised ratio increased 122.92 14.31 135 30305 86637 110472222
Thrombosis 118.80 14.31 148 30292 108514 110450345
Constipation 114.77 14.31 283 30157 357503 110201356
Diabetes mellitus 114.52 14.31 139 30301 99242 110459617
Total lung capacity decreased 114.00 14.31 50 30390 7064 110551795
Blood test abnormal 104.38 14.31 76 30364 28478 110530381
Chronic obstructive pulmonary disease 104.15 14.31 139 30301 109019 110449840
Troponin increased 103.79 14.31 77 30363 29689 110529170
Hyperlipidaemia 103.71 14.31 83 30357 35765 110523094
Congenital hiatus hernia 103.58 14.31 45 30395 6214 110552645
Bronchopulmonary aspergillosis allergic 99.79 14.31 48 30392 8378 110550481
Ulcer 98.27 14.31 87 30353 43029 110515830
Abdominal pain 95.37 14.31 334 30106 512655 110046204
Coagulopathy 84.29 14.31 78 30362 40833 110518026
General physical health deterioration 80.81 14.31 279 30161 425016 110133843
Bacteroides infection 75.81 14.31 29 30411 2890 110555969
Pulmonary embolism 75.52 14.31 176 30264 214298 110344561
Lung opacity 74.46 14.31 44 30396 11608 110547251
Intentional product misuse 72.84 14.31 131 30309 132773 110426086
Anaemia 72.27 14.31 320 30120 546766 110012093
Transaminases increased 71.92 14.31 88 30352 63302 110495557
Cystic fibrosis 71.77 14.31 32 30408 4699 110554160
Rheumatoid arthritis 69.63 14.31 3 30437 299610 110259249
Hepatic failure 66.26 14.31 88 30352 68651 110490208
Benign prostatic hyperplasia 63.18 14.31 47 30393 18187 110540672
Somnolence 60.73 14.31 200 30240 297249 110261610
Dizziness 59.19 14.31 63 30377 698130 109860729
Joint swelling 52.85 14.31 28 30412 442817 110116042
Hyper IgE syndrome 50.93 14.31 15 30425 666 110558193
Pleuritic pain 50.18 14.31 39 30401 16101 110542758
Dry mouth 49.67 14.31 144 30296 199804 110359055
Aspiration 49.39 14.31 51 30389 30482 110528377
Pain 48.31 14.31 121 30319 954834 109604025
Fall 47.28 14.31 58 30382 603424 109955435
Systemic lupus erythematosus 46.95 14.31 7 30433 254331 110304528
Cardiovascular disorder 46.12 14.31 43 30397 22717 110536142
Micturition urgency 46.05 14.31 40 30400 19280 110539579
Pericarditis 45.51 14.31 4 30436 219110 110339749
Haemoptysis 45.18 14.31 75 30365 71279 110487580
Mobility decreased 45.08 14.31 6 30434 237416 110321443
Product use issue 44.72 14.31 15 30425 311680 110247179
Therapeutic product effect decreased 44.47 14.31 7 30433 244309 110314550
Factor V inhibition 44.38 14.31 12 30428 389 110558470
Sleep disorder 41.80 14.31 135 30305 198509 110360350
Hepatic encephalopathy 41.79 14.31 45 30395 28211 110530648
Contraindicated product administered 41.15 14.31 9 30431 248258 110310601
Blood cholesterol increased 41.09 14.31 128 30312 184657 110374202
Blood creatinine increased 40.96 14.31 127 30313 182762 110376097
Hypersensitivity 39.45 14.31 32 30408 403966 110154893
Arthralgia 39.23 14.31 99 30341 779533 109779326
Acute hepatic failure 38.75 14.31 49 30391 36419 110522440
Helicobacter infection 38.66 14.31 3 30437 181874 110376985
Breath sounds abnormal 38.53 14.31 41 30399 25363 110533496
Toxicity to various agents 37.81 14.31 46 30394 480509 110078350
Vomiting 37.50 14.31 399 30041 910276 109648583
Type 2 diabetes mellitus 37.45 14.31 3 30437 177229 110381630
Treatment failure 36.97 14.31 15 30425 277219 110281640
Nasopharyngitis 36.35 14.31 33 30407 394328 110164531
Wound 35.93 14.31 10 30430 234427 110324432
Pleural effusion 35.79 14.31 119 30321 177590 110381269
Hyperbilirubinaemia 35.46 14.31 43 30397 30628 110528231
Drug abuse 34.86 14.31 4 30436 177407 110381452
Peripheral swelling 34.70 14.31 36 30404 403998 110154861
Respiratory symptom 33.73 14.31 30 30410 14915 110543944
Hepatic enzyme increased 33.12 14.31 24 30416 320868 110237991
Blister 32.51 14.31 11 30429 227365 110331494
Pancreatitis acute 32.47 14.31 59 30381 60215 110498644
Arthritis 32.38 14.31 4 30436 167582 110391277
Aspartate aminotransferase increased 32.12 14.31 107 30333 159829 110399030
Intentional product use issue 32.11 14.31 14 30426 247892 110310967
Impaired healing 30.88 14.31 8 30432 196709 110362150
Pruritus 30.68 14.31 72 30368 581488 109977371
Abdominal discomfort 30.66 14.31 38 30402 393820 110165039
Renal vascular thrombosis 30.59 14.31 7 30433 112 110558747
Hypoaesthesia 30.52 14.31 25 30415 314198 110244661
Infusion related reaction 30.49 14.31 36 30404 381126 110177733
Injury 30.25 14.31 6 30434 177259 110381600
Ill-defined disorder 29.68 14.31 4 30436 156849 110402010
Cutaneous mucormycosis 29.28 14.31 10 30430 720 110558139
Psoriatic arthropathy 29.04 14.31 9 30431 196752 110362107
Prothrombin time prolonged 28.22 14.31 29 30411 17232 110541627
Joint injury 27.99 14.31 44 30396 39950 110518909
Thrombocytopenia 27.99 14.31 178 30262 348707 110210152
Depression 26.43 14.31 29 30411 317306 110241553
Symmetrical drug-related intertriginous and flexural exanthema 26.14 14.31 12 30428 1885 110556974
Osteochondritis 25.99 14.31 5 30435 32 110558827
Gait disturbance 25.96 14.31 23 30417 278185 110280674
Rash 25.95 14.31 127 30313 820837 109738022
Bursitis 25.34 14.31 3 30437 129915 110428944
Sputum discoloured 24.23 14.31 34 30406 27911 110530948
Blood bilirubin increased 23.13 14.31 59 30381 75913 110482946
Malaise 22.95 14.31 101 30339 671718 109887141
Pain in extremity 22.83 14.31 64 30376 487054 110071805
Pulmonary function test decreased 22.75 14.31 19 30421 8681 110550178
Respiratory failure 22.58 14.31 118 30322 215214 110343645
Muscle spasms 22.53 14.31 26 30414 278131 110280728
Discomfort 22.22 14.31 16 30424 214691 110344168
Back pain 21.98 14.31 43 30397 370953 110187906
Sinusitis 21.67 14.31 30 30410 296658 110262201
Stevens-Johnson syndrome 21.66 14.31 43 30397 46858 110512001
Cholestasis 21.65 14.31 52 30388 64466 110494393
Cystic fibrosis related diabetes 21.45 14.31 6 30434 221 110558638
Subdural haematoma 21.33 14.31 37 30403 36417 110522442
Anxiety 21.32 14.31 39 30401 345039 110213820
Transverse sinus thrombosis 21.18 14.31 8 30432 770 110558089
Paraesthesia 21.17 14.31 27 30413 276494 110282365
Osteoarthritis 21.10 14.31 12 30428 182611 110376248
Pancreatic failure 20.80 14.31 11 30429 2343 110556516
Factor VII deficiency 20.66 14.31 5 30435 103 110558756
Gait inability 20.55 14.31 6 30434 136370 110422489
Fatigue 20.54 14.31 225 30215 1215733 109343126
Abdominal tenderness 20.49 14.31 21 30419 12436 110546423
Disseminated intravascular coagulation 20.47 14.31 39 30401 41247 110517612
Migraine 20.24 14.31 11 30429 171641 110387218
Stomatitis 20.06 14.31 27 30413 270215 110288644
Vitamin K deficiency 19.87 14.31 8 30432 913 110557946
Road traffic accident 19.71 14.31 3 30437 107395 110451464
Pneumonia staphylococcal 19.55 14.31 15 30425 6076 110552783
Discoloured vomit 19.47 14.31 10 30430 2007 110556852
Liver function test increased 19.36 14.31 61 30379 88487 110470372
Muscular weakness 19.29 14.31 24 30416 248444 110310415
Immune effector cell-associated neurotoxicity syndrome 19.20 14.31 22 30418 14760 110544099
Acute respiratory distress syndrome 19.07 14.31 44 30396 53154 110505705
Joint range of motion decreased 19.03 14.31 5 30435 121827 110437032
Myocardial infarction 19.00 14.31 15 30425 192068 110366791
Cortical visual impairment 18.87 14.31 4 30436 44 110558815
Restrictive cardiomyopathy 18.78 14.31 8 30432 1053 110557806
Coagulation time prolonged 18.60 14.31 11 30429 2906 110555953
Alopecia 18.54 14.31 46 30394 364707 110194152
Hyphaema 18.45 14.31 8 30432 1099 110557760
Weight increased 18.31 14.31 57 30383 419587 110139272
Jaundice 18.03 14.31 46 30394 59190 110499669
Intentional overdose 17.93 14.31 7 30433 132494 110426365
Adverse event 17.91 14.31 4 30436 108805 110450054
Cytokine release syndrome 17.79 14.31 51 30389 70255 110488604
Mouth haemorrhage 17.40 14.31 20 30420 13468 110545391
Retroperitoneal haematoma 17.31 14.31 14 30426 6117 110552742
Wound infection 17.02 14.31 3 30437 96462 110462397
Rales 17.01 14.31 27 30413 24712 110534147
Heparin-induced thrombocytopenia 16.55 14.31 18 30422 11406 110547453
Drug reaction with eosinophilia and systemic symptoms 16.54 14.31 55 30385 82040 110476819
Full blood count abnormal 16.52 14.31 43 30397 56009 110502850
Insomnia 16.43 14.31 48 30392 360542 110198317
Tumour lysis syndrome 16.40 14.31 30 30410 30771 110528088
Bronchiectasis 16.31 14.31 33 30407 36460 110522399
Iatrogenic infection 15.94 14.31 4 30436 96 110558763
Therapy non-responder 15.92 14.31 12 30428 157295 110401564
Neutropenic colitis 15.88 14.31 15 30425 8050 110550809
Distal intestinal obstruction syndrome 15.76 14.31 7 30433 1018 110557841
Contusion 15.67 14.31 25 30415 233336 110325523
Urticaria 15.60 14.31 41 30399 318816 110240043
Obesity 15.32 14.31 6 30434 113345 110445514
Memory impairment 15.31 14.31 19 30421 196925 110361934
Amnesia 15.23 14.31 5 30435 105403 110453456
Bacteraemia 15.12 14.31 35 30405 42355 110516504
Superior sagittal sinus thrombosis 14.97 14.31 7 30433 1146 110557713
C-reactive protein increased 14.96 14.31 23 30417 217896 110340963
Epileptic encephalopathy 14.95 14.31 6 30434 679 110558180
Dermatitis exfoliative 14.93 14.31 17 30423 11330 110547529
Musculoskeletal pain 14.93 14.31 17 30423 183006 110375853
Epidermolysis 14.83 14.31 7 30433 1171 110557688
Suicide attempt 14.77 14.31 5 30435 103389 110455470
Epistaxis 14.75 14.31 73 30367 130299 110428560
Pancreatitis chronic 14.34 14.31 11 30429 4454 110554405

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B02BA01 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Vitamin K
FDA CS M0022806 Vitamin K
MeSH PA D000933 Antifibrinolytic Agents
MeSH PA D003029 Coagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D006490 Hemostatics
MeSH PA D014815 Vitamins
MeSH PA D018977 Micronutrients
FDA PE N0000175965 Increased Prothrombin Activity
FDA EPC N0000175966 Warfarin Reversal Agent
FDA PE N0000175982 Reversed Anticoagulation Activity
FDA EPC N0000180191 Vitamin K
CHEBI has role CHEBI:23357 cofactor
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:50646 bone density conservation agent
CHEBI has role CHEBI:64951 anti-HBV agent
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:76924 plant metabolite
CHEBI has role CHEBI:77746 human metabolite
CHEBI has role CHEBI:233423 antifibrotic agent
CHEBI has role CHEBI:24020 fat-soluble vitamin (role)
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:75771 mouse metabolite

Related Drugs by ATC class:

B02BA Vitamin K 1 drug
menadione

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypocalcemia indication 5291005
Osteoporosis indication 64859006 DOID:11476
Factor II deficiency indication 73975000
Postmenopausal osteoporosis indication 102447009
Prevention of Neonatal Hemorrhagic Disease indication
Antibiotic-Induced Hypoprothrombinemia indication
Neonatal Hemorrhagic Disease indication
Vitamin K Deficiency Induced Hypoprothrombinemia indication
Anticoagulant-Induced Prothrombin Deficiency indication
Obstruction of bile duct off-label use 30144000
Abetalipoproteinemia off-label use 190787008 DOID:1386
Constipation contraindication 14760008 DOID:2089
Hyperphosphatemia contraindication 20165001 DOID:0050459
Hypervitaminosis D contraindication 27712000 DOID:9971
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
Vitamin E deficiency contraindication 54137008
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Anemia due to enzyme deficiency contraindication 111577008
Neoplasm of endometrium contraindication 123844007 DOID:1380
Neoplasm of prostate contraindication 126906006 DOID:10283
Osteolysis contraindication 203522001
Arteriosclerosis obliterans contraindication 361133006 DOID:5160
Malignant tumor of cervix contraindication 363354003 DOID:4362
Central nervous system depression contraindication 418072004
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML MULTIPLE VITAMINS INJECTION ADULT APOTEX A210672 April 9, 2026 RX SOLUTION INTRAVENOUS Dec. 1, 2026 COMPETITIVE GENERIC THERAPY
80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL MULTIPLE VITAMINS INJECTION PEDIATRIC APOTEX A210671 April 21, 2026 RX INJECTABLE INTRAVENOUS Dec. 21, 2026 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-synuclein Transporter IC50 4.82 CHEMBL

External reference:

IDSource
4017772 VUID
N0000146136 NUI
D00148 KEGG_DRUG
81818-54-4 SECONDARY_CAS_RN
4017772 VANDF
4018981 VANDF
4021719 VANDF
4021911 VANDF
C0031862 UMLSCUI
CHEBI:18067 CHEBI
PQN PDB_CHEM_ID
CHEMBL1550 ChEMBL_ID
CHEMBL1201519 ChEMBL_ID
DB01022 DRUGBANK_ID
5284607 PUBCHEM_CID
11258 RXNORM
1433 MMSL
15677 MMSL
199215 MMSL
42273 MMSL
5298 MMSL
d03135 MMSL
001038 NDDF
001042 NDDF
63136007 SNOMEDCT_US
65183007 SNOMEDCT_US
66656000 SNOMEDCT_US
74226000 SNOMEDCT_US
D010837 MESH_DESCRIPTOR_UI
D014812 MESH_DESCRIPTOR_UI
177 INN_ID
A034SE7857 UNII
A034SE7857 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9935 INJECTION, EMULSION 1 mg PARENTERAL ANDA 17 sections
PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9935 INJECTION, EMULSION 1 mg PARENTERAL ANDA 17 sections
PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9969 INJECTION, EMULSION 10 mg INTRAMUSCULAR ANDA 12 sections
PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9969 INJECTION, EMULSION 10 mg INTRAMUSCULAR ANDA 12 sections
Vitamin K1 HUMAN PRESCRIPTION DRUG LABEL 1 0409-9157 INJECTION, EMULSION 2 mg INTRAMUSCULAR ANDA 29 sections
Vitamin K1 HUMAN PRESCRIPTION DRUG LABEL 1 0409-9157 INJECTION, EMULSION 2 mg INTRAMUSCULAR ANDA 29 sections
Vitamin K1 HUMAN PRESCRIPTION DRUG LABEL 1 0409-9158 INJECTION, EMULSION 10 mg INTRAMUSCULAR ANDA 29 sections
Vitamin K1 HUMAN PRESCRIPTION DRUG LABEL 1 0409-9158 INJECTION, EMULSION 10 mg INTRAMUSCULAR ANDA 29 sections
Phytonadione HUMAN PRESCRIPTION DRUG LABEL 1 0904-6882 TABLET 5 mg ORAL ANDA 22 sections
Phytonadione HUMAN PRESCRIPTION DRUG LABEL 1 16714-973 TABLET 5 mg ORAL ANDA 21 sections
MEPHYTON HUMAN PRESCRIPTION DRUG LABEL 1 21695-168 TABLET 5 mg ORAL NDA 21 sections
Phytonadione HUMAN PRESCRIPTION DRUG LABEL 1 25021-505 INJECTION, EMULSION 1 mg INTRAVENOUS ANDA 27 sections
PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 43066-132 INJECTION, EMULSION 1 mg INTRAMUSCULAR ANDA 24 sections
PHYTONADIONE PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 43598-405 INJECTION, EMULSION 10 mg INTRAMUSCULAR ANDA 19 sections
Phytonadione Human Prescription Drug Label 1 46708-826 INJECTION, EMULSION 1 mg INTRAMUSCULAR ANDA 24 sections
Mephyton HUMAN PRESCRIPTION DRUG LABEL 1 50090-1753 TABLET 5 mg ORAL NDA 20 sections
Vitamin K1 HUMAN PRESCRIPTION DRUG LABEL 1 50090-4521 INJECTION, EMULSION 10 mg INTRAMUSCULAR ANDA 19 sections
Vitamin K1 HUMAN PRESCRIPTION DRUG LABEL 1 50090-4523 INJECTION, EMULSION 2 mg INTRAMUSCULAR ANDA 19 sections
Phytonadione HUMAN PRESCRIPTION DRUG LABEL 1 50228-333 TABLET 5 mg ORAL ANDA 21 sections
VITAMIN K1 - PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1536 INJECTION, EMULSION 10 mg INTRAMUSCULAR ANDA 13 sections
VITAMIN K1 PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1537 INJECTION, EMULSION 2 mg INTRAMUSCULAR ANDA 13 sections
PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1698 INJECTION, EMULSION 10 mg INTRAVENOUS ANDA 14 sections
PHYTONADIONE HUMAN PRESCRIPTION DRUG LABEL 1 52584-043 INJECTION, EMULSION 1 mg PARENTERAL ANDA 13 sections
Phytonadione HUMAN PRESCRIPTION DRUG LABEL 1 52584-240 INJECTION, EMULSION 1 mg PARENTERAL ANDA 13 sections
Adult Infuvite Multiple Vitamins HUMAN PRESCRIPTION DRUG LABEL 13 54643-9007 INJECTION, SOLUTION 150 ug INTRAVENOUS NDA 20 sections
Adult Infuvite Multiple Vitamins HUMAN PRESCRIPTION DRUG LABEL 13 54643-9015 INJECTION, SOLUTION 150 ug INTRAVENOUS NDA 20 sections
Pediatric Infuvite Multiple Vitamins HUMAN PRESCRIPTION DRUG LABEL 13 54643-9023 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 19 sections
Pediatric Infuvite Multiple Vitamins HUMAN PRESCRIPTION DRUG LABEL 13 54643-9023 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 19 sections
Mephyton HUMAN PRESCRIPTION DRUG LABEL 1 54868-5438 TABLET 5 mg ORAL NDA 22 sections
Diatrol HUMAN PRESCRIPTION DRUG LABEL 17 59088-162 TABLET 90 ug ORAL unapproved drug other 11 sections